Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

[18F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration.

Orfeas Vourkas Linda Zhang Andrés Jiménez-Pérez Cristina Sánchez-Martín Marina Fernandez-Alvarez Alberto Rábano P. Sánchez-Juan J. Silva-Rodríguez M. Grothe
Jul 2026 · European Journal of Nuclear Medicine and Molecular Imaging · Vol 53, pp. 7504-7513 · 0 citations · 28 references
Medicine

TL;DR

Hypometabolism is a sensitive and early marker of AD-related neurodegeneration, preceding MRI-detectable GM atrophy and more closely reflecting underlying tau pathology across disease stages.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Jul 2026

Structural MRI signature predicts tau staging in Alzheimer's disease

Abstract INTRODUCTION Tau positron emission tomography (PET) probes Alzheimer's disease (AD) severity via regional tau spread but is not widely available. We tested whether multiregion structural magnetic resonance imaging (MRI) could approximate individual tau burden. METHODS We studied 378 Alzheimer's Disease Neuroim...

Martina Pulze, S. Garbarino, L. Lorenzini et al. · 0 citations
Open access Aug 2026

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Summary Background Reduced [18F]Fluorodeoxyglucose ([18F]FDG)-PET uptake is a core imaging feature of Alzheimer's disease (AD). While tau load correlates with this metabolic signature, it remains unclear whether the spatial extent of tauopathy (SEOT) more accurately explains brain glucose hypometabolic patterns. Here,...

Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al. · 1 citation
Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · 0 citations
Review Open access Sep 2026

A review of FDG-PET biomarker analysis methods in Parkinson's disease

Despite well-established clinical diagnostic criteria for Parkinson's disease (PD), challenges remain in early-stage diagnosis, differentiating atypical parkinsonism disorders, and understanding of underlying disease mechanisms. Neuroimaging, particularly positron emission tomography (PET) with [18F]fluorodeoxyglucose...

Erik Reimers, C. Bevington, A. Stoessl et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.